Form 8-K ALNYLAM PHARMACEUTICALS, For: Nov 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Alnylam Pharma (ALNY), Medicines Co. (MDCO) Announce Positive Data from Ongoing ALN-PCSsc Phase 1
November 11, 2015 10:47 AM ESTAlnylam Pharma (NASDAQ: ALNY) and The Medicines Company (Nasdaq: MDCO) reported positive results from their ongoing Phase 1 clinical trial with ALN-PCSsc in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2015.
ALN-PCSsc is an investigational RNAi therapeutic... More
Alnylam Pharma (ALNY) Reports In-Line Q3 EPS
November 9, 2015 7:13 AM ESTAlnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($0.91), in-line with the analyst estimate of ($0.91). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $7.55 million.
"The past quarter and recent period were marked by tremendous progress in our efforts to... More
